ERBB2 and lung carcinoma: In a study by Negrao M. V. et al., oncogene-dependent lung cancers (including alterations in EGFR (epidermal growth factor receptor), KRAS (Kirsten rat sarcoma virus), BRAFV600E (v-raf murine sarcoma viral oncogene homolog B1), HER2 (human epidermal growth factor receptor 2), MET exon 14 skipping mutations, and RET, ROS1, and ALK (Anaplastic lymphoma kinase) gene fusions/rearrangements) exhibit variable TMB expression and outcomes with ICIs, generally showing a low TMB (<10 mut/Mb) among these common oncogenic groups [62].